Partnering With Brilliant People, Delivering Distributions, Recruiting An Analyst & Hopefully Improving Our World

/
Partnering With Brilliant People, Delivering Distributions, Recruiting An Analyst & Hopefully Improving Our World

We are thrilled to share that we have returned our LDV Capital I & II funds. We continue to have significant upside potential across each of our funds thanks to our brilliant entrepreneurs, experts, team and LP partners.

We continue investing out of our LDV Capital IV fund. 

LPs say we are highly differentiated, disciplined, have high-quality sourcing and successfully create value by investing in category leaders at the earliest stages.

We are excited to be recruiting an Analyst to join our team to help us identify, analyze and evaluate investment opportunities. You will be a major contributor to all aspects of our fund from sourcing, market research, due diligence and supporting our portfolio companies.

Read More

3 Years Investing at LDV Capital: Insights from Sourcing, Evaluating & Partnering with Early-Stage Deep Tech Founders

/
3 Years Investing at LDV Capital: Insights from Sourcing, Evaluating & Partnering with Early-Stage Deep Tech Founders

In September 2021, Ash Cleary began his venture capital journey by joining Evan Nisselson and our LDV Capital team as an Analyst, investing out of Fund III as part of a two-year program. After successfully completing the program, Ash was promoted to Associate and now invests out of LDV Capital's fourth fund.

Check out his insights and reflections on the past three years—working with the team and collaborating with brilliant deep tech entrepreneurs worldwide, building businesses powered by visual technology and artificial intelligence.

Read More

The Age of New Medicines: How AI is Empowering & Disrupting the Discovery of Proteins, Biologics, Therapeutics & Materials

/
The Age of New Medicines: How AI is Empowering & Disrupting the Discovery of Proteins, Biologics, Therapeutics & Materials

Meet Dr. Molly Gibson – Co-Founder and Chief Strategy & Innovation Officer at Generate:Biomedicines, Origination Partner at Flagship Pioneering. LDV Capital's Founder & General Partner Evan Nisselson discussed with Molly how AI and machine learning empower and disrupt the scientific process across life sciences, biotech, advanced materials and more.

If you missed our 10th Annual LDV Vision Summit, this is your chance to watch the video or read our shortened & lightly edited transcript.

Read More

The Age of New Medicines: How AI is Empowering & Disrupting the Discovery of Proteins, Biologics, Therapeutics & Materials

/
The Age of New Medicines: How AI is Empowering & Disrupting the Discovery of Proteins, Biologics, Therapeutics & Materials

On March 21, at our 10th Annual LDV Vision Summit, Evan Nisselson, Founder and General Partner at LDV Capital, will speak with Dr. Molly Gibson – Co-Founder and Chief Strategy and Innovation Officer at Generate:Biomedicines. They will discuss how AI and machine learning empower and disrupt the scientific process across life sciences, biotech, advanced materials, and more. This will have a tremendous impact on business and society. 

In the lead-up to the Summit, Evan had the privilege of asking Dr. Gibson a few questions.

Read More

LDV Capital Raised Fourth Fund To Continue Investing in People Building Businesses Powered by Visual Technologies and Artificial Intelligence

/

We are pleased to announce that we have raised our fourth LDV Capital fund with $31M. We will continue investing in the same unique thesis that has not changed since founding LDV Capital in 2012. The majority of data our brains analyze is visual so the majority of data that AI will analyze will be visual as well. Visual data and visual technologies are critical for the success of artificial intelligence horizontally across all sectors.

Read More

Living Longer & Healthier: How Visual Tech will Advance Accelerations in Life Sciences & Biotech

/
Living Longer & Healthier: How Visual Tech will Advance Accelerations in Life Sciences & Biotech

As the biotech industry relies heavily on data filtering, analysis and sharing, visual technologies will become critical for the detection and imaging of biological systems, paving the way for the future of life sciences tools enabling next-generation therapeutics, biomanufacturing & longevity.

Read More

Generative AI As A Utility Will Empower SaaS Businesses

/
Generative AI As A Utility Will Empower SaaS Businesses

We at LDV Capital have been investing in AI for over 10 years to date, and have made 7 investments in teams building businesses leveraging Generative AI since 2018. We believe that this technology has significant commercial value as a utility that will empower SaaS businesses to disrupt legacy enterprises. Check out this article to learn more and see some examples of exponentially growing commercial applications in content creation, biotech and more.

Read More

Interview with Dr. Sujatha Ramanujan, Managing Director of Luminate – an Accelerator for Startups with Optics, Photonics and Imaging Enabled Technologies

/
Interview with Dr. Sujatha Ramanujan, Managing Director of Luminate – an Accelerator for Startups with Optics, Photonics and Imaging Enabled Technologies

The next guest in our Women Leading Visual Tech series is Dr. Sujatha Ramanujan, a serial entrepreneur and seasoned executive with 25 years of experience in medical devices and consumer electronics. She currently serves as the Managing Director of Luminate – the world’s largest accelerator for startups with optics, photonics, and imaging enabled applications. LDV Capital’s Abigail Hunter-Syed spoke with Sujatha about managing a crisis, fear of boredom, and a mission to revitalize the Rochester area.

Read More